Onxeo Announces Participation in the Midcap Event on October 2nd and 3rd, 2014 in Paris

PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Regulatory News:

Onxeo SA (Paris:ONXEO) (NASDAQ OMX:ONXEO), an innovative company specialized in
the development of drugs for orphan oncology diseases, announced that it will
participate in the Midcap Event, a forum dedicated to meetings between
institutional investors and listed companies from the Euronext Zone, on Thursday
2nd and Friday 3rd of October, 2014 in Paris (Palais Brongniart, 28, place de la
Bourse - 75002 Paris - Entry Vivienne).

During these two days, Onxeo Management team will meet with institutional
investors to present the Company and its development strategy.

About Onxeo
Onxeo has the vision to become a global leader and pioneer in oncology, with a
focus on orphan or rare cancers, through developing innovative therapeutic
alternatives to “make the difference”. The Onxeo teams are determined to develop
innovative medicines to provide patients with hope and significantly improve
their lives.
Key products at advanced development stage are:
Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive® (Clonidine Lauriad®): Phase II in severe oral mucositis
Beleodaq® (belinostat): Registered and available in the USA for peripheral T
-cell lymphoma
For more information, visit the website www.onxeo.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Onxeo and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors, which could cause the
actual results, financial condition, performance or achievements of Onxeo to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is providing this
communication as of this date and does not undertake to update any forward
-looking statements contained herein as a result of new information, future
events or otherwise. For a discussion of risks and uncertainties which could
cause actual results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference
Document filed with the AMF on April 7, 2014, which is available on the AMF
website (http://www.amf-france.org) or on the company’s website (www.onxeo.com).
CONTACT:

Onxeo
Judith Greciet, CEO
j.greciet@onxeo.com
+33 1 45 58 76 00
or
Nicolas Fellmann, CFO
n.fellmann@onxeo.com
+33 1 45 58 76 00
or
Caroline Carmagnol / Sophie Colin – Alize RP
caroline@alizerp.com / scolin@alizerp.com
+33 6 64 18 99 59 / +33 6 31 13 76 20